Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTPN1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTPN1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTPN1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTPN1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTPN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578716 | Skin | AK | positive regulation of cell cycle | 58/1910 | 313/18723 | 5.08e-06 | 1.19e-04 | 58 |
GO:00518949 | Skin | AK | positive regulation of focal adhesion assembly | 12/1910 | 28/18723 | 7.83e-06 | 1.72e-04 | 12 |
GO:003812719 | Skin | AK | ERBB signaling pathway | 29/1910 | 121/18723 | 9.23e-06 | 1.98e-04 | 29 |
GO:000195419 | Skin | AK | positive regulation of cell-matrix adhesion | 18/1910 | 58/18723 | 1.09e-05 | 2.29e-04 | 18 |
GO:005086317 | Skin | AK | regulation of T cell activation | 59/1910 | 329/18723 | 1.20e-05 | 2.46e-04 | 59 |
GO:001081127 | Skin | AK | positive regulation of cell-substrate adhesion | 29/1910 | 123/18723 | 1.29e-05 | 2.58e-04 | 29 |
GO:003459927 | Skin | AK | cellular response to oxidative stress | 53/1910 | 288/18723 | 1.56e-05 | 3.05e-04 | 53 |
GO:000716210 | Skin | AK | negative regulation of cell adhesion | 55/1910 | 303/18723 | 1.64e-05 | 3.15e-04 | 55 |
GO:004682523 | Skin | AK | regulation of protein export from nucleus | 12/1910 | 30/18723 | 1.83e-05 | 3.47e-04 | 12 |
GO:000715919 | Skin | AK | leukocyte cell-cell adhesion | 64/1910 | 371/18723 | 1.87e-05 | 3.52e-04 | 64 |
GO:003109917 | Skin | AK | regeneration | 40/1910 | 198/18723 | 1.88e-05 | 3.52e-04 | 40 |
GO:00717743 | Skin | AK | response to fibroblast growth factor | 28/1910 | 120/18723 | 2.23e-05 | 4.08e-04 | 28 |
GO:004593117 | Skin | AK | positive regulation of mitotic cell cycle | 28/1910 | 121/18723 | 2.62e-05 | 4.65e-04 | 28 |
GO:004343425 | Skin | AK | response to peptide hormone | 69/1910 | 414/18723 | 2.87e-05 | 4.98e-04 | 69 |
GO:000961217 | Skin | AK | response to mechanical stimulus | 42/1910 | 216/18723 | 3.07e-05 | 5.21e-04 | 42 |
GO:000661118 | Skin | AK | protein export from nucleus | 17/1910 | 57/18723 | 3.40e-05 | 5.68e-04 | 17 |
GO:007137517 | Skin | AK | cellular response to peptide hormone stimulus | 52/1910 | 290/18723 | 3.86e-05 | 6.35e-04 | 52 |
GO:190165320 | Skin | AK | cellular response to peptide | 61/1910 | 359/18723 | 4.60e-05 | 7.21e-04 | 61 |
GO:00427709 | Skin | AK | signal transduction in response to DNA damage | 35/1910 | 172/18723 | 5.20e-05 | 8.05e-04 | 35 |
GO:00420637 | Skin | AK | gliogenesis | 53/1910 | 301/18723 | 5.42e-05 | 8.29e-04 | 53 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0452042 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa0452052 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0452016 | Lung | IAC | Adherens junction | 37/1053 | 93/8465 | 1.99e-11 | 2.16e-09 | 1.43e-09 | 37 |
hsa0520816 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
hsa0452017 | Lung | IAC | Adherens junction | 37/1053 | 93/8465 | 1.99e-11 | 2.16e-09 | 1.43e-09 | 37 |
hsa0520817 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | inhibitor | 252827507 | | |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | OLEANOLIC_ACID | OLEANOLIC_ACID | 21453996 |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | inhibitor | 384403654 | | |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | ALLYL ISOTHIOCYANATE | ALLYL ISOTHIOCYANATE | 26338358 |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | LICOAGRODIN | LICOAGRODIN | 24047800 |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | REL-HUEAFURANOID A | CHEMBL2207339 | 23141910 |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | ISIS 113715 | | |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | TILUDRONATE | TILUDRONIC ACID | |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | GLISOFLAVONE | GLISOFLAVONE | 20724155 |
5770 | PTPN1 | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, ENZYME, KINASE | | INSULIN | INSULIN | 8826975 |